|
1
|
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.
|
Cell Metab
|
2012
|
1.97
|
|
2
|
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
1.41
|
|
3
|
The STAT-MI (ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction) trial improves outcomes.
|
JACC Cardiovasc Interv
|
2011
|
1.13
|
|
4
|
A management algorithm for esophageal perforation.
|
Am J Surg
|
2007
|
1.10
|
|
5
|
Internal hernia after laparoscopic Roux-en-Y gastric bypass.
|
Surg Obes Relat Dis
|
2005
|
1.03
|
|
6
|
Physical activity and quality of life improvements before obesity surgery.
|
Am J Health Behav
|
2006
|
0.88
|
|
7
|
Right ventricular failure in patients with preserved ejection fraction and diastolic dysfunction: an underrecognized clinical entity.
|
Congest Heart Fail
|
2007
|
0.84
|
|
8
|
The effect of a single remote course versus weekly courses of antenatal corticosteroids on functional residual capacity in preterm infants: a randomized trial.
|
Pediatrics
|
2002
|
0.82
|
|
9
|
Altered esophageal sensory-motor function in patients with persistent symptoms after Nissen fundoplication.
|
Am J Surg
|
2007
|
0.81
|
|
10
|
Extensive myocardial iron deposition in a patient with hepatitis C.
|
Tex Heart Inst J
|
2012
|
0.77
|
|
11
|
Unicuspid unicommissural aortic valve: an extremely rare congenital anomaly.
|
Tex Heart Inst J
|
2015
|
0.75
|
|
12
|
Complementary non-culprit revascularization during ST-elevation myocardial infarction…get to know your patient first to the editor.
|
Catheter Cardiovasc Interv
|
2011
|
0.75
|
|
13
|
New oral anticoagulants: good but not good enough!
|
J Am Coll Cardiol
|
2012
|
0.75
|
|
14
|
Right coronary artery anatomical variants: where and how?
|
J Invasive Cardiol
|
2010
|
0.75
|
|
15
|
Hypertension in African Americans with heart failure: progression from hypertrophy to dilatation; perhaps not.
|
High Blood Press Cardiovasc Prev
|
2014
|
0.75
|
|
16
|
The functional SYNTAX score - a huge step forward or research in motion?
|
J Invasive Cardiol
|
2012
|
0.75
|
|
17
|
Optimizing primary PCI beyond "door to intervention time"--are we there yet?
|
Cardiovasc Revasc Med
|
2010
|
0.75
|